Loading...
| A11711 | Pages: 266 | Jun 2021 | 197 Views | | |
| Author(s) : Snehal Manjrekar, Trupti Wadekar , Onkar Sumant | Tables: 143 | Charts: 35 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Endoscopy Devices For Obesity, Type Ii Diabetes And Nash Market
Request Now !The global endoscopy devices for obesity, type II diabetes and NASH market was valued at $2,638.99 million in 2019, and is projected to reach $3,711.43 million by 2028, registering a CAGR of 7.6% from 2021 to 2028. Endoscopy devices are used in the endoscopic procedures that lie between the medication based treatment and surgical treatment because they provide better weight loss. These devices reduce the cases of side effects which are generally experienced with medications, but they call for less introduction of surgical instruments and other devices into the body cavity than other surgical options. Likewise, endoscopy procedures are non-surgical procedures that utilize endoscopy devices and supplies to examine the interior of a patient’s digestive tract. Endoscopy may also be used to treat disorders, such as obesity, type II diabetes and NASH. These procedures are mainly preferred owing to their advantages such as less invasiveness, length of stay at hospitals, and cost savings in terms of pre- and post-operative care.
Surge in prevalence of obesity across the globe has been supplemented by growing frequency in its associated comorbid ailments including coronary heart disease, stroke, hypertension, diabetes, dyslipidemia, gallbladder disease, GERD, nonalcoholic fatty liver disease (NAFLD), sleep apnea, osteoarthritis, and cancer. Obesity is linked with major risk of mortality and accounts for almost 2.5 million avoidable deaths every year. The economic concerns of obesity are huge, and estimated increase may jeopardize the integrity of health care systems globally. Overweightness and obesity among individuals are some of the main drivers of metabolic diseases and NAFLD across the globe and may require some type of surgery. However, not all patients are qualified for surgical treatment, which in turn, is responsible for driving the demand for endoscopic procedures in near future. On the other hand, dearth of trained physicians & endoscopists and infections associated with the use of endoscopes are expected to hinder the growth of the market.
Get more information on this report : Request Sample Pages
COVID-19 pandemic has affected endoscopy devices production and import & export of raw material and finished goods, owing to shutdowns in various COVID-19 affected countries, and rise in number of healthcare workers falling ill in the pandemic, leading to short supply. Temporary disruptions of inputs or production might stress some companies, particularly those with inadequate liquidity. Moreover, delayed shipments & production schedules create financial problems for companies with heavy debts. This, in turn, has negatively impacted the market growth.
The major reason for decline in endoscopy procedures during the COVID-19 pandemic was the decrease in patient volume in hospitals, owing to rescheduling and delaying of procedures for safety reasons.
Moreover, these delays happened after careful review of patient history and if feasible, healthcare providers rescheduled endoscopic procedures to minimize the risk of getting exposed to COVID-19 during hospital visits. Furthermore, regions that are severely affected by COVID-19, have reduced endoscopy procedures, owing to new government directives or hospital guidelines. Thus, the overall impact of the COVID-19 pandemic on the endoscopy devices for obesity, type II diabetes and NASH market is fairly negative.
On the basis of product, the market is categorized into endoscope, mechanical endoscopic equipment, visualization & documentation systems, accessories, and other endoscopy equipment. The endoscope segment accounted for the largest revenue in 2019. Advancements in the endoscopy devices for its use in weight loss procedures have created numerous opportunities for endoscope manufacturers worldwide.
Get more information on this report : Request Sample Pages
Manufacturers have focused on the development of proprietary technology platforms to differentiate from the competitors to take advantage of these opportunities. In addition, they have developed cost-effective and patent-protected proprietary solutions to stand-alone and maintain their positions in the endoscopy devices for obesity, type II diabetes, and NASH market. Moreover, endoscopes are used in the weight loss surgeries such as gastric balloon, aspiration therapy, endoscopic sleeve gastroplasty, gastric injection, and lap band surgery while implanting as well as removing these implants from a patient’s body. Gastric balloon uses a soft durable balloon that is inserted into stomach through mouth with the help of endoscope. Endoscopic sleeve gastroplasty uses suturing devices which are inserted into the stomach through mouth with the help of endoscope and sutures are placed in the stomach to make it smaller. Thus, this increase in adoption of endoscopes in minimally invasive procedures for weight loss management are anticipated to propel the segment growth throughout forecast period.
By procedure, the endoscopy devices for obesity, type II diabetes and NASH market is classified into gastric balloons, aspiration therapy, endoscopic sleeve gastroplasty, gastric injections, and lap band surgery.
Get more information on this report : Request Sample Pages
Endoscopic sleeve gastroplasty segment is estimated to grow at a substantial pace during the forecast period, as it offers long term relief from weight gain and obesity. Furthermore, rise in prevalence of diseases related to obesity and awareness about obesity treatments coupled with advances in minimally invasive procedures are the major factors anticipated to drive the growth of the endoscopy devices for obesity, type II diabetes and NASH market for endoscopic sleeve gastroplasty segment during the forecast period. Moreover, ongoing clinical trials with respect to endoscopic sleeve gastroplasty procedures are anticipated to boost the segment growth in the coming years. For instance, a randomized interventional clinical study on safety and efficacy endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with NASH (TESLA-NASH) using Overstitch device is under investigation. Thus, surge in popularity of such procedures among obese patient population is expected to drive the growth of the endoscopy devices for obesity, type II diabetes and NASH market.
By disease indication, the endoscopy devices for obesity, type II diabetes, and NASH market is classified into obesity, type II diabetes, and nonalcoholic steatohepatitis (NASH). The type II diabetes segment is anticipated to garner largest share in the market throughout the analysis period. According to several research studies conducted, individuals with severe obesity are at greater risk of type II diabetes than people with a lower BMI. Being overweight (BMI of 25-29.9), obese (BMI of 30-39.9) or morbid obese (BMI of 40 or greater), greatly increases the insulin resistance in muscles and tissues in the human body. For instance, Diabetes.co.uk (one of the largest diabetes community in Europe), in 2019, stated that obesity is supposed to account for 80-85% of the risk of developing type II diabetes, whereas recent research indicates that obese people are up to 80 times more likely to develop type II diabetes than those with a BMI of less than 22. Therefore, rise in incidences of diabetes among population is estimated to drive the growth of the endoscopy for obesity, type II diabetes, and NASH devices market.
Get more information on this report : Request Sample Pages
Europe accounted for a major share in the endoscopy devices for obesity, type II diabetes, and NASH market in 2019, and is expected to maintain its dominance during the forecast period, owing to surge in obese population, technological advancements, rise in prevalence rate of diseases that require endoscopy devices, growth in patient preference for minimally invasive surgeries, favorable CE approvals and reimbursement policies in developed economies, shorter recovery time and minimal postoperative complications. Asia-Pacific endoscopy devices for obesity, type II diabetes, and NASH market is expected to register significant growth rate during the forecast period, owing to rise in prevalence rate of diseases that require endoscopy devices and technological advancements in the region.
Get more information on this report : Request Sample Pages
The report provides a comprehensive analysis of the key players that operate in the global endoscopy devices for obesity, type II diabetes and NASH market such as Apollo Endosurgery, Fractyl Laboratories, GI Dynamics, GI Windows, Aspire Bariatrics, Reshape LifeSciences, Inc., USGI Medical, Obalon Therapeutics, Spatz Fgia and Endo Tools Therapeutics.
Key Benefits For Stakeholders
Key Market Segments
By Product
By Procedure
By Disease indication
By Region
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in obese population
3.5.1.2.Technological advancements
3.5.1.3.Rise in prevalence rate of diseases that require endoscopy devices
3.5.1.4.Growth in patient preference for minimally invasive surgeries
3.5.1.5.Favorable FDA approvals
3.5.1.6.Shorter recovery time and minimal postoperative complications
3.5.2.Restraints
3.5.2.1.Dearth of trained physicians and endoscopists
3.5.2.2.Infections caused by few endoscopes
3.5.3.Opportunities
3.5.3.1.Unmet medical demands in developing countries
3.5.3.2.Lucrative opportunities in emerging economies
3.6.COVID-19 impact analysis
3.7.Clinical data analysis
3.7.1.Intragastric balloons
3.7.2.AspireAssist
3.7.3.Revita DMR System
3.7.4.EndoBarrier
3.7.5.Incision-less Anastomosis System (IAS)
3.7.6.OverStitch Endoscopic Suturing System
3.7.7.Endomina
3.7.8.Plication Device
3.7.9.Endostitch
CHAPTER 4:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Endoscopes
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Mechanical endoscopic equipment
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Visualization and documentation systems
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Accessories
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Other endoscopy equipment
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
CHAPTER 5:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE
5.1.Overview
5.1.1.Market size and forecast
5.2.Gastric balloons
5.2.1.Key market trends and opportunities
5.2.2.Market size and forecast
5.2.3.Market analysis, by country
5.3.Aspiration therapy
5.3.1.Key trends and opportunities
5.3.2.Market size and forecast
5.3.3.Market analysis, by country
5.4.Endoscopic sleeve gastroplasty
5.4.1.Key market trends and opportunities
5.4.2.Market size and forecast
5.4.3.Market analysis, by country
5.5.Gastric injections
5.5.1.Key market trends and opportunities
5.5.2.Market size and forecast
5.5.3.Market analysis, by country
5.6.Lap band surgery
5.6.1.Key market trends and opportunities
5.6.2.Market size and forecast
5.6.3.Market analysis, by country
5.7.Others
5.7.1.Key market trends and opportunities
5.7.2.Market size and forecast
5.7.3.Market analysis, by country
CHAPTER 6:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Obesity
6.2.1.Key market trends, growth factors and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market share analysis, by country
6.3.Type II Diabetes
6.3.1.Key market trends, growth factors and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market share analysis, by country
6.4.Nonalcoholic Steatohepatitis (NASH)
6.4.1.Key market trends, growth factors and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market share analysis, by country
CHAPTER 7:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by product type
7.2.4.Market size and forecast, by procedure
7.2.5.Market size and forecast, by disease indication
7.2.5.1.U.S.
7.2.5.1.1.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.1.2.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.1.3.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.2.5.2.Canada
7.2.5.2.1.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.2.2.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.2.3.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.2.5.3.Mexico
7.2.5.3.1.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.2.5.3.2.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.2.5.3.3.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.1.2.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.1.3.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.2.France
7.3.2.2.1.France Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.2.2.France Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.2.3.France Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.3.U.K.
7.3.2.3.1.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.3.2.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.3.3.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.4.Italy
7.3.2.4.1.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.4.2.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.4.3.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.5.Spain
7.3.2.5.1.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.5.2.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.5.3.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.3.2.6.2.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.3.2.6.3.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by product type
7.4.4.Market size and forecast, by procedure
7.4.5.Market size and forecast, by disease indication
7.4.5.1.China
7.4.5.1.1.China Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.1.2.China endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.1.3.China endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.2.Japan
7.4.5.2.1.Japan Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.2.2.Japan endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.2.3.Japan endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.3.India
7.4.5.3.1.India Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.3.2.India endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.3.3.India endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.4.Australia
7.4.5.4.1.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.4.2.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.4.3.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.4.5.5.Rest of Asia-Pacific
7.4.5.5.1.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.4.5.5.2.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.4.5.5.3.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by product type
7.5.4.Market size and forecast, by procedure
7.5.5.Market size and forecast, by disease indication
7.5.5.1.Brazil
7.5.5.1.1.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.1.2.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.1.3.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.2.2.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.2.3.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.3.South Africa
7.5.5.3.1.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.3.2.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.3.3.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by product type
7.5.5.4.2.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
7.5.5.4.3.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
CHAPTER 8:COMPANY PROFILES
8.1.APOLLO ENDOSURGERY INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.ASPIRE BARIATRICS INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segment
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.ENDO TOOLS THERAPEUTICS S.A.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segment
8.3.4.Product portfolio
8.4.FRACTYL LABORATORIES INC.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segment
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments
8.5.GI DYNAMICS INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segment
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments
8.6.GI WINDOWS INC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segment
8.6.4.Product portfolio
8.6.5.Key strategic moves and developments
8.7.MEDTRONIC PLC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.OBALON THERAPEUTICS INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segment
8.8.4.Product portfolio
8.8.5.Business Performance
8.9.RESHAPE LIFESCIENCES INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance
8.9.5.Key strategic moves and developments
8.10.SPATZ FGIA INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segment
8.10.4.Product portfolio
8.11.USGI MEDICAL INC.
8.11.1.Company overview
8.11.2.Company snapshot
8.11.3.Operating business segments
8.11.4.Product portfolio
8.11.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.OVERVIEW OF FDA STATUS FOR DEVICES USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 02.CLINICAL DATA OF THE GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 03.CLINICAL DATA OF THE OTHER GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 04.CLINICAL PIPELINE ANALYSIS OF GASTRIC BALLOONS
TABLE 05.CLINICAL DATA OF THE ASPIRATION THERAPY DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 06.CLINICAL PIPELINE ANALYSIS OF ASPIRATION THERAPY DEVICE
TABLE 07.CLINICAL DATA OF THE REVITA DMR SYSTEM USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 08.CLINICAL PIPELINE ANALYSIS OF REVITA DMR SYSTEM
TABLE 09.CLINICAL DATA OF ENDOBARRIER USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 10.CLINICAL PIPELINE ANALYSIS OF ENDOBARRIER
TABLE 11.CLINICAL DATA OF INCISION-LESS ANASTOMOSIS SYSTEM (IAS) USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 12.CLINICAL PIPELINE ANALYSIS OF INCISIONLESS ANASTOMOSIS
TABLE 13.CLINICAL DATA OF OVERSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 14.CLINICAL PIPELINE ANALYSIS OF OVERSTITCH ENDOSCOPIC SUTURING SYSTEM
TABLE 15.CLINICAL DATA OF ENDOMINA USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 16.CLINICAL PIPELINE ANALYSIS OF ENDOMINA
TABLE 17.CLINICAL DATA OF PLICATION DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 18.CLINICAL PIPELINE ANALYSIS OF PLICATION DEVICE
TABLE 19.CLINICAL DATA OF ENDOSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
TABLE 20.CLINICAL PIPELINE ANALYSIS OF ENDOSTITCH
TABLE 21.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019–2028 ($MILLION)
TABLE 22.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY REGION, 2019–2028 ($MILLION)
TABLE 23.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY REGION, 2019–2028 ($MILLION)
TABLE 24.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEM, BY REGION, 2019–2028 ($MILLION)
TABLE 25.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY REGION, 2019–2028 ($MILLION)
TABLE 26.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY REGION, 2019–2028 ($MILLION)
TABLE 27.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019–2028 ($MILLION)
TABLE 28.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY REGION, 2019–2028 ($MILLION)
TABLE 29.ENDOSOCOPY DEVICES MARKET FOR ASPIRATION THEREAPY, BY REGION, 2019–2028 ($MILLION)
TABLE 30.ENDOSCOPIC DEVICES MARKET FOE ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2019–2028 ($MILLION)
TABLE 31.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTION, BY REGION, 2019–2028 ($MILLION)
TABLE 32.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET LAP BAND SURGERY, BY REGION, 2019–2028 ($MILLION)
TABLE 33.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET OTHERS, BY REGION, 2019–2028 ($MILLION)
TABLE 34.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION 2019-2028($MILLION)
TABLE 35.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY REGION, 2019-2028 ($MILLION)
TABLE 36.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY REGION, 2019-2028 ($MILLION)
TABLE 37.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY REGION, 2019-2028 ($MILLION)
TABLE 38.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION, 2019-2028 ($MILLION)
TABLE 39.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 40.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 41.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 42.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 43.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028
TABLE 44.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 45.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 46.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 47.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 48.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 49.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 50.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 51.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 52.EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 53.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 54.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 55.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 56.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 57.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 58.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 59.U.K. ENDOSCOPY DEVICES MARKET FOR OBESITY, TYPE II DIABETES, AN BGT5D NASH, BY PRODUCT, 2019-2028
TABLE 60.U.K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 61.U.K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 62.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 63.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 64.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 65.SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 66.SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 67.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 68.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 69.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 70.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 71.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 72.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 73.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 74.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 75.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 76.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 77.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 78.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 79.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 80.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 81.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 82.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 83.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 84.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 85.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 86.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 87.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 88.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 89.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 90.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
TABLE 91.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
TABLE 92.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
TABLE 93.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
TABLE 94.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 95.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 96.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 97.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 98.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 99.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 100.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 101.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 102.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 103.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
TABLE 104.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
TABLE 105.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
TABLE 106.APOLLO ENDOSURGERY: COMPANY SNAPSHOT
TABLE 107.APOLLO ENDOSURGERY: OPERATING SEGMENT
TABLE 108.APOLLO ENDOSURGERY: PRODUCT PORTFOLIO
TABLE 109.ASPIRE BARIATRICS: COMPANY SNAPSHOT
TABLE 110.ASPIRE BARIATRICS: OPERATING SEGMENT
TABLE 111.ASPIRE BARIATRICS: PRODUCT PORTFOLIO
TABLE 112.ASPIRE BARIATRICS: PRODUCT PORTFOLIO
TABLE 113.ENDO TOOLS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 114.ENDO TOOLS THERAPEUTICS: OPERATING SEGMENT
TABLE 115.ENDO TOOLS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 116.FRACTYL LABORATORIES: COMPANY SNAPSHOT
TABLE 117.FRACTYL LABORATORIES: OPERATING SEGMENTS
TABLE 118.FRACTYL LABORATORIES: PRODUCT PORTFOLIO
TABLE 119.FRACTYL LABORATORIES: PRODUCT PORTFOLIO
TABLE 120.GI DYNAMICS: COMPANY SNAPSHOT
TABLE 121.GI DYNAMICS: OPERATING SEGMENT
TABLE 122.GI DYNAMICS: PRODUCT PORTFOLIO
TABLE 123.GI DYNAMICS: PRODUCT PORTFOLIO
TABLE 124.GI WINDOWS: COMPANY SNAPSHOT
TABLE 125.GI WINDOWS: OPERATING SEGMENT
TABLE 126.GI WINDOWS: PRODUCT PORTFOLIO
TABLE 127.GI WINDOWS: PRODUCT PORTFOLIO
TABLE 128.MEDTRONIC: COMPANY SNAPSHOT
TABLE 129.MEDTRONIC: OPERATING BUSINESS SEGMENTS
TABLE 130.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 131.OBALON THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE 132.OBALON THERAPEUTICS: OPERATING SEGMENT
TABLE 133.OBALON THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 134.RESHAPE LIFESCIENCES: COMPANY SNAPSHOT
TABLE 135.RESHAPE LIFESCIENCES INC.: PRODUCT PORTFOLIO
TABLE 136.RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 137.SPATZ FGIA: COMPANY SNAPSHOT
TABLE 138.SPATZ FGIA: OPERATING SEGMENT
TABLE 139.SPATZ FGIA: PRODUCT PORTFOLIO
TABLE 140.USGI MEDICAL: COMPANY SNAPSHOT
TABLE 141.USGI MEDICAL: OPERATING SEGMENTS
TABLE 142.USGI MEDICAL: PRODUCT PORTFOLIO
TABLE 143.RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL ENDOSCOPY DEVICES MARKET: SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021*
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021*
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.HIGH INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.DRIVERS, RESTRAINTS, OPPORTUNITIES
FIGURE 08.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEMS, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY COUNTRY, 2019 & 2028 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES MARKET FOR ASPIRATION THERAPY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTIONS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR LAP BAND SURGERY, BY COUNTRY, 2019 & 2028 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2028 (%)
FIGURE 19.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY COUNTRY, 2019 & 2028
FIGURE 20.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY COUNTRY, 2019 & 2028
FIGURE 21.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY COUNTRY, 2019 & 2028
FIGURE 22.REGION WISE PREVALENCE OF DIABETES, 2019, 2030 & 2045
FIGURE 23.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 24.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 25.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 26.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
FIGURE 27.APOLLO ENDOSURGERY: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.APOLLO ENDOSURGERY: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.APOLLO ENDOSURGERY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.MEDTRONIC: NET SALES, 2018–2020 ($MILLION
FIGURE 31.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.MEDTRONIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.OBALON THERAPEUTICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.RESHAPE LIFESCIENCES INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 35.RESHAPE LIFESCIENCES: REVENUE SHARE BY REGION, 2020 (%)
The endoscopy devices for obesity, type II diabetes and NASH market is expected to witness a healthy growth with the rise in demand for minimally invasive surgical procedures. The endoscopy devices for obesity, type II diabetes and NASH market has pulled interest of the healthcare industry, owing to rise in number of endoscopy procedures and increase in use of these devices in emerging applications to diagnose and treat obesity and its comorbid conditions. In addition, favorable FDA approvals pertaining to endoscopy devices in developed economies, surge in patient preference for minimally invasive surgeries, and shorter recovery time & minimal postoperative complications drive the growth of the global endoscopy devices for obesity, type II diabetes and NASH market. On the contrary, unmet medical demands in developing countries are expected to provide remunerative opportunities for market expansion.
Increase in awareness regarding technologically advanced devices and rise in knowledge about weight loss procedures are expected to boost demand for endoscopy devices. Therefore, use of endoscopy devices in treating obesity and diabetes is expected to increase in the future.
A. The total market value of Endoscopy Devices for Obesity, Type II Diabetes and NASH market is $2,638.99 million in 2019
A. The forecast period in the report is from 2021 to 2028
A. The market value of Endoscopy Devices for Obesity, Type II Diabetes and NASH market in 2020 was $2,818.44 Million
A. The base year for the report is 2019
A. Yes, Endoscopy Devices for Obesity, Type II Diabetes and NASH Market companies are profiled in the report
A. The top companies that hold the market share in Endoscopy Devices for Obesity, Type II Diabetes and NASH market are Apollo Endosurgery, Aspire Bariatrics, Reshape LifeSciences, Inc., and, Obalon Therapeutics.
A. No, there is no value chain analysis provided in the Endoscopy Devices for Obesity, Type II Diabetes and NASH market report
A. The key trends in the Endoscopy Devices for Obesity, Type II Diabetes and NASH market are Surge in obese population and Growth in patient preference for minimally invasive surgeries
Enterprise
License/PDF
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
